Foster Wheeler Ltd. (Nasdaq: FWLT) announced today that its Singapore subsidiary Foster Wheeler Eastern Private Limited, part of its Global Engineering and Construction Group, has been awarded an engineering, procurement, construction management and commissioning services contract by GlaxoSmithKline Biologicals for a new biotechnology production facility in Singapore.
The value of the contract was not disclosed. The engineering and procurement services were included in Foster Wheeler's first-quarter 2007 bookings and the construction management and commissioning services will be included in its third-quarter 2007 bookings.
This state-of-the-art facility includes two production buildings, a quality control and administration building, and a utilities building, all on a site of more than 8.8 hectares in Tuas Biomedical Park, in Singapore.
'This latest award from GSK Biologicals reflects our client's continued confidence in the quality of our people and in our biotechnology expertise and track record,' said Franco Anselmi, chief executive officer of Foster Wheeler Asia Pacific. 'Key to our success in winning this contract was the performance of the Foster Wheeler team on GSK Biologicals' new vaccine facility in Hungary, which is now complete, and our ability to leverage this successful experience for the new Singaporean facility. In addition, our 30-year track record of delivering safe and successful projects in Singapore strongly demonstrates our position as one of the leading engineering, procurement and construction contractors in Singapore.'